These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 24198620)

  • 1. Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle.
    Berruti A; Vignani F; Russo L; Bertaglia V; Tullio M; Tucci M; Poggio M; Dogliotti L
    Open Access J Urol; 2010 Jul; 2():109-24. PubMed ID: 24198620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neuroendocrine differentiation in prostate cancer. An unrecognized and therapy-resistant phenotype].
    Bonkhoff H; Fixemer T
    Urologe A; 2004 Jul; 43(7):836-42. PubMed ID: 15048555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
    Alberti C
    G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
    Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
    J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The influence of neuroendocrine differentiation on the growth and androgen receptor expression of prostate carcinoma cells].
    Song Y; Wu G; Xin DQ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(23):1453-6. PubMed ID: 15733464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
    Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Function and molecular mechanisms of neuroendocrine cells in prostate cancer.
    Huang J; Wu C; di Sant'Agnese PA; Yao JL; Cheng L; Na Y
    Anal Quant Cytol Histol; 2007 Jun; 29(3):128-38. PubMed ID: 17672372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer.
    Terry S; Maillé P; Baaddi H; Kheuang L; Soyeux P; Nicolaiew N; Ceraline J; Firlej V; Beltran H; Allory Y; de la Taille A; Vacherot F
    Neoplasia; 2013 Jul; 15(7):761-72. PubMed ID: 23814488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation.
    Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Prostate; 2002 Mar; 50(4):203-15. PubMed ID: 11870798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities.
    Vashchenko N; Abrahamsson PA
    Eur Urol; 2005 Feb; 47(2):147-55. PubMed ID: 15661408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine pathogenesis in adenocarcinoma of the prostate.
    Hansson J; Abrahamsson PA
    Ann Oncol; 2001; 12 Suppl 2():S145-52. PubMed ID: 11762343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence.
    Ito T; Yamamoto S; Ohno Y; Namiki K; Aizawa T; Akiyama A; Tachibana M
    Oncol Rep; 2001; 8(6):1221-4. PubMed ID: 11605036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine differentiation in prostate cancer.
    Cerović SJ; Brajusković GR; Vukotić Maletić VD; Mićić SR
    Vojnosanit Pregl; 2004; 61(5):513-8. PubMed ID: 15551804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The many faces of neuroendocrine differentiation in prostate cancer progression.
    Terry S; Beltran H
    Front Oncol; 2014; 4():60. PubMed ID: 24724054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of neuroendocrine differentiation in prostate adenocarcinoma.
    Sagnak L; Topaloglu H; Ozok U; Ersoy H
    Clin Genitourin Cancer; 2011 Dec; 9(2):73-80. PubMed ID: 22035833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies.
    Conteduca V; Aieta M; Amadori D; De Giorgi U
    Crit Rev Oncol Hematol; 2014 Oct; 92(1):11-24. PubMed ID: 24952997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells.
    Moritz T; Venz S; Junker H; Kreuz S; Walther R; Zimmermann U
    Tumour Biol; 2016 Aug; 37(8):10435-46. PubMed ID: 26846108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neuroendocrine differentiation in prostate cancer: an unrecognized and therapy resistant phenotype].
    Bonkhoff H; Fixemer T
    Pathologe; 2005 Nov; 26(6):453-60. PubMed ID: 16195860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression.
    Deng X; Liu H; Huang J; Cheng L; Keller ET; Parsons SJ; Hu CD
    Cancer Res; 2008 Dec; 68(23):9663-70. PubMed ID: 19047143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
    Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
    Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.